CA15-3
- Aliases
-
- ADMCKD
- ADMCKD1
- Breast Carcinoma-Associated Antigen DF3
- CA 15-3
- CA15-3
- CA15.3
- CD227
- CD227 Antigen
- Cancer Antigen 15-3
- Carcinoma-Associated Mucin
- DF3 Antigen
- EMA
- Episialin
- H23 Antigen
- H23AG
- KL-6
- Krebs Von Den Lungen-6
- MAM6
- MCD
- MCKD
- MCKD1
- MUC-1
- MUC-1/SEC
- MUC-1/X
- MUC1
- MUC1/ZD
- Medullary Cystic Kidney Disease 1 (Autosomal Dominant)
- Medullary Cystic Kidney Disease, Autosomal Dominant
- Mucin 1, Cell Surface Associated
- Mucin 1, Transmembrane
- Mucin-1
- PEM
- PEMT
- PUM
- Peanut-Reactive Urinary Mucin
- Polymorphic Epithelial Mucin
- Tumor Associated Epithelial Mucin
- Tumor-Associated Epithelial Membrane Antigen
- Tumor-Associated Mucin
- Description
- From NCBI Gene: This gene encodes a membrane-bound protein that is a member of the mucin family. Mucins are O-glycosylated proteins that play an essential role in forming protective mucous barriers on epithelial surfaces. These proteins also play a role in intracellular signaling. This protein is expressed on the apical surface of epithelial cells that line the mucosal surfaces of many different tissues including lung, breast stomach and pancreas. This protein is proteolytically cleaved into alpha and beta subunits that form a heterodimeric complex. The N-terminal alpha subunit functions in cell-adhesion and the C-terminal beta subunit is involved in cell signaling. Overexpression, aberrant intracellular localization, and changes in glycosylation of this protein have been associated with carcinomas. This gene is known to contain a highly polymorphic variable number tandem repeats (VNTR) domain. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Feb 2011]
Attributes
- QA State
- Accepted
- Type
- Protein
- HGNC Name
- MUC1
- Certifications
-
- None
- QA State for Breast
- Curated
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- Certifications
-
- None
- QA State for Lung
- Under Review
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- Certifications
-
- None
- QA State for Ovary
- Accepted
Organ-Specific Notes
CA15-3 may be a molecular marker for ovarian cancer. Literature suggests that the concomitant measurement of CA15-3 with CA125 could be advantageous in the pre-operative discrimination of benign and malignant ovarian tumors.
Performance Comment
Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. CA15-3 alone was not a strong predictor.
Supporting Study Data
PLCO Ovarian Phase III Validation Study
SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study
Ovary-Specific Protocols
- No organ-level protocols specified for ovary.
Ovary-Specific Publications
- No organ-level publications were listed for ovary.
Ovary-Specific Resources
- No organ-level resources were given for ovary.
- Certifications
-
- None
- QA State for Prostate
- Under Review
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- BRSCW Reference Set Application: Anna Lokshin - Univ of Pitts (2008)
- Benign Breast Disease Team Project
- Breast Reference Set Application: Anu Mathew-Meso Scale (2012)
- Breast Reference Set Application: GeorgeTuszynski-Temple (2012)
- Canary TMA
- PLCO Ovarian Phase III Validation Study
- SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study
- A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.
- A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.
- Autoantibodies in lung cancer: possibilities for early detection and subsequent cure.
- Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease.
- Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
- Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.
- Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays.
- Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
- The state of molecular biomarkers for the early detection of lung cancer.